An overarching aim of precision medicine is to direct the right treatment to the right person at the right dose at the right time. Recently, mendelian randomization (MR) studies have contributed to our evidence base for precision medicine by harnessing genetic information to assess whether associations of exposures with cardiovascular outcomes may be causal. The ascendance of MR studies takes advantage of the explosive growth of genome-wide genetic data in multiple cohorts collaborating within global meta-analyses. In MR studies, genetic variants associated with an exposure of interest serve as unconfounded proxies for altered levels of the exposure.1
O’Donnell CJ. Mendelian Randomization Evidence for Cardiovascular Precision Medicine. JAMA Cardiol. 2018;3(7):627–628. doi:https://doi.org/10.1001/jamacardio.2018.1543
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: